astrazeneca drug failure
shares drug closed failure iressa drug clinical
lung cancer drug prolong survival patients disease setback rejection pill exanta spinners cholesterol drug crestor mounting safety blockbuster drugs meant failing risks crestor nick turner analyst brokers jefferies
astrazeneca hoped pitch iressa drug rival medicine tarceva iressa proved placebo extending lives involving patients tarceva osi pharmaceuticals genentech roche proved successful helping prolong lung cancer patients aztrazeneca appointed patterson drug patterson substantial clinical processes determined regulatory restore confidence shareholders tom mckillop
